SCHEMBL5154002

SCHEMBL5154002

O=C(CN1C(=O)C(=C2SC(=S)N(CCS(=O)(=O)O)C2=O)c2ccccc21)Nc1cccc(C(F)(F)F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 1.00
CTDSP1 Q9GZU7 3/20 1.00
CCR6 P51684 2/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
KMT2A Q03164 6/20 0.79
MEN1 O00255 5/20 0.79
MCL1 Q07820 4/20 0.79
POLB P06746 2/20 0.79
CACNA1B Q00975 2/20 0.79
APBA1 Q02410 2/20 0.79
USP2 O75604 1/20 0.79
PKM P14618 1/20 0.79
DUSP3 P51452 1/20 0.79
PTPN7 P35236 1/20 0.54
APOBEC3G Q9HC16 1/20 0.54
PTPN22 Q9Y2R2 1/20 0.54
APEX1 P27695 3/20 0.50
PTGES O14684 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5630999 1.00 TDP1 (1.00) TDP1CTDSP1CCR6L3MBTL1KMT2A
SCHEMBL14440266 0.91 TDP1 (0.84) TDP1CTDSP1CCR6L3MBTL1KMT2A
SCHEMBL14440259 0.89 KMT2A (0.82) TDP1CTDSP1CCR6L3MBTL1KMT2A
SCHEMBL2083915 0.89 KMT2A (0.82) TDP1CTDSP1CCR6L3MBTL1KMT2A
SCHEMBL4551958 0.85 KMT2A (0.75) TDP1CTDSP1CCR6L3MBTL1KMT2A
SCHEMBL4551957 0.85 KMT2A (0.75) TDP1CTDSP1CCR6L3MBTL1KMT2A
SCHEMBL4551955 0.85 KMT2A (0.75) TDP1CTDSP1CCR6L3MBTL1KMT2A
SCHEMBL4551586 0.85 CTDSP1 (0.74) TDP1CTDSP1CCR6L3MBTL1KMT2A
SCHEMBL4551585 0.85 CTDSP1 (0.74) TDP1CTDSP1CCR6L3MBTL1KMT2A
SCHEMBL4551587 0.85 CTDSP1 (0.74) TDP1CTDSP1CCR6L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179137-A1 Screening of anti-viral drugs and pharmaceuticals composition containing thiazolidinone derivatives RIMONYX PHARMACEUTICALS LTD. (IL) 2007-08-02 US claimed
EP-1738170-A2 SCREENING OF ANTI-VIRAL DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THIAZOLIDINONE DERIVATIVES Rimonyx Pharmaceuticals Ltd. (IL) 2007-01-03 EP claimed
WO-2005089067-A2 SCREENING OF ANTI-VIRAL DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THIAZOLIDINONE DERIVATIVES RIMONYX PHARMACEUTICALS LTD. (IL) 2005-09-29 WO claimed
US-20070179137-A1 Screening of anti-viral drugs and pharmaceuticals composition containing thiazolidinone derivatives RIMONYX PHARMACEUTICALS LTD. (IL) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179137-A1 Screening of anti-viral drugs and pharmaceuticals composition containing thiazolidinone derivatives ABCG2, LGALS3BP, GBA3 TDP1 2038/4885CTDSP1 807/4885CCR6 2132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.